Literature DB >> 3809596

Tumor excision and radiotherapy as primary treatment of breast cancer. Analysis of patient and treatment parameters and local control.

E van Limbergen, W van den Bogaert, E van der Schueren, A Rijnders.   

Abstract

From 1966 to 1979, 235 patients with operable breast cancer were treated by tumor excision and radiotherapy. The actuarial survival at 10 years was 94.8% for stage I and 58% for stage II tumors. Local recurrent cancer was seen in 23/235 patients and was related to T stage, N stage, width of surgical excision, radiation dose to the tumor bed and anatomopathological differentiation. Recurrences were seen in 1/7 of T0, 3/57 (5.2%) of T1, 11/102 (10.8%) of T2 and 2/6 of T3 tumors. Local control in the breast decreased significantly in N1b cases (p = 0.005) or when 3 or more axillary lymph nodes were positive (p = 0.0074). Local control after segmentectomy or tumorectomy was identical. However, a poorer local control was found in 20 cases treated with subtotal resection (p less than 0.05). A clear dose-local control relationship was found in this material, with a 100% local control in all T0, T1 tumors which received more than 1800 ret and all T2 tumors which received more than 2000 ret. As 19 of 23 breast recurrences were seen at the primary site in the breast we believe that booster doses should be given in order to maximise local control.

Entities:  

Mesh:

Year:  1987        PMID: 3809596     DOI: 10.1016/s0167-8140(87)80016-6

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  15 in total

1.  Preliminary Results of Quadrantectomy and Radiation Therapy for Breast Cancer.

Authors: 
Journal:  Breast Cancer       Date:  1994-12-30       Impact factor: 4.239

2.  Management of breast cancer.

Authors:  J M Dixon
Journal:  BMJ       Date:  1992-07-11

Review 3.  Recent developments and best practice in brachytherapy treatment planning.

Authors:  C D Lee
Journal:  Br J Radiol       Date:  2014-06-02       Impact factor: 3.039

Review 4.  The role of boost irradiation in the conservative treatment of stage I-II breast cancer.

Authors:  C Polgár; J Fodor; T Major; Z Orosz; G Németh
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

Review 5.  Risk factors and management of local recurrence following breast conservation surgery.

Authors:  R T Osteen
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

6.  Uncertainty of cosmetic evaluation after accelerated partial breast irradiation: interim analysis of a Japanese prospective multi-institutional feasibility study.

Authors:  Eisaku Yoden; Takayuki Nose; Yuki Otani; Shuuji Asahi; Iwao Tsukiyama; Takushi Dokiya; Toshiaki Saeki; Ichirou Fukuda; Hiroshi Sekine; Naoto Shikama; Yu Kumazaki; Takao Takahashi; Ken Yoshida; Tadayuki Kotsuma; Norikazu Masuda; Kazutaka Nakashima; Taisei Matsumura; Shino Nakagawa; Seiji Tachiiri; Yoshio Moriguchi; Jun Itami; Masahiko Oguchi
Journal:  Jpn J Radiol       Date:  2017-05-04       Impact factor: 2.374

7.  The optimal extent of resection for patients with stages I or II breast cancer treated with conservative surgery and radiotherapy.

Authors:  F A Vicini; T J Eberlein; J L Connolly; A Recht; A Abner; S J Schnitt; W Silen; J R Harris
Journal:  Ann Surg       Date:  1991-09       Impact factor: 12.969

8.  Breast conservation therapy: local tumor control in patients with pathologically clear margins who receive 5000 cGy breast irradiation without local boost.

Authors:  R D Pezner; L D Wagman; J Ben-Ezra; T Odom-Maryon
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 9.  Synchronous bilateral breast cancer patients submitted to conservative treatment and brachytherapy - The experience of a service.

Authors:  Joana Pinheiro; Darlene Rodrigues; Pedro Fernandes; Alexandre Pereira; Lurdes Trigo
Journal:  Rep Pract Oncol Radiother       Date:  2018-08-13

10.  Impact of an extensive in situ component on the presence of residual disease in screen detected breast cancer.

Authors:  I D Campbell; J M Theaker; G T Royle; R Coddington; R Carpenter; A Herbert; I Moore; C Rubin; I Taylor; P B Guyer
Journal:  J R Soc Med       Date:  1991-11       Impact factor: 18.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.